Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Access and Reimbursement Insights Report – 2025

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Access and Reimbursement Insights

Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity resulting from the use of neurotoxic antineoplastic agents, most notably taxanes, platinum compounds, and vinca alkaloids. The pathogenesis involves multifaceted damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to the dorsal root ganglia, which are particularly vulnerable due to their high metabolic activity and permeable blood-nerve barrier. Clinically, CIPN manifests as a symmetric sensory impairment in a “glove-and-stocking” distribution, characterized by numbness, paresthesia, and burning pain, and may involve a “coasting” effect where symptoms progress even after treatment cessation. Risk is exacerbated by cumulative drug exposure, advanced age, and pre-existing conditions like diabetes. As there are currently no FDA-approved agents for the prevention of CIPN, management is primarily symptomatic—with the SNRI duloxetine serving as the first-line evidence-based intervention—while severe symptoms often necessitate clinical dose delays or permanent discontinuation of life-saving chemotherapy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Chemotherapy-Induced Peripheral Neuropathy (CIPN) – Market Access and Reimbursement Insights Report – 2025